Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia

Summary

This is an open-label, phase I clinical study of F182112 in patients with relapsed or refractory autoimmune hemolytic anemia (AIHA). Participants will receive F182112 at different dose levels. The main purpose of the study is to evaluate the safety and tolerability of F182112 and to identify an appropriate dose for further clinical development.

Timeline

Start

2026-10-10

Primary completion

2027-12-31

Completion

2028-12-31

Drugs

Indications